Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Mariana S A FerrazDepartment of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA, 92093, USA.
Michael ReissShu Chien-Gene Lay Department of Bioengineering, School of Engineering, University of California San Diego, La Jolla, CA, 92093, USA.ORCID http://orcid.org/0009-0009-2885-2276
Angels Almenar-QueraltDepartment of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA, 92093, USA.
Georgia ChaldaiopoulouDepartment of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA, 92093, USA.ORCID http://orcid.org/0000-0002-0142-6113
Janaina Sena de SouzaDepartment of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA, 92093, USA.ORCID http://orcid.org/0000-0003-3904-7458
Francisco DowneyNanotools Bioscience, La Jolla, CA, 92037, USA.
Omowuyi O OlajideShu Chien-Gene Lay Department of Bioengineering, School of Engineering, University of California San Diego, La Jolla, CA, 92093, USA.ORCID http://orcid.org/0009-0002-5398-531X
Alysson R MuotriDepartment of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA, 92093, USA. muotri@ucsd.edu.ORCID http://orcid.org/0000-0003-0867-2875
Spinal Circuits for the Control of Dextrous MovementU19NS112959 · NINDS · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI AZIM, EIMAN · 2019 to 2023
$14.3M
Novel SETD5-based Molecular Mechanisms and Therapeutic Tools to Understand and Revert Neuronal Dysfunction Associated with Intellectual disability and AutismR01MH127077 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Alon Goren, Alysson R. Muotri · 2022 to 2026
$3.9M
Brain pathology and function in a chronic mouse model of ZIKV transmissionR01NS105969 · NINDS · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI MUOTRI, ALYSSON R., OLSON, STEVEN H · 2019 to 2023
$3.3M
Characterization of spinal circuits underlying motor synergy functionR01NS123160 · NINDS · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI PFAFF, SAMUEL L. · 2021 to 2025
$3.0M
Investigating neurodevelopmental toxicity of perfluoroalkyl acids and their derivatives in human brain organoids modelsR01ES033636 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LILIA M IAKOUCHEVA, Alysson R. Muotri · 2022 to 2026
$3.0M
Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for the treatment of opioid use disorderR44DA050393 · NIDA · NEURANO BIOSCIENCE · PI MOLOKANOVA, ELENA · 2023 to 2025
$2.5M
The Impact of hiPSC-Derived Microglia in Human Brain Development in Health and DiseaseR01NS123642 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MUOTRI, ALYSSON R. · 2021 to 2025
$2.2M
Investigation of Pitt-Hopkins Syndrome pathophysiology using a human modelR01MH123828 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MUOTRI, ALYSSON R. · 2021 to 2025
$1.9M
Dissecting local (N) and long range (Z) circuit modules within the spinal cordR01NS135055 · NINDS · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI SAMUEL L. PFAFF · 2024 to 2026
$1.6M
Cortical organoid models to study autism-associated 16p.11.2.CNVR56MH128365 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IAKOUCHEVA, LILIA M, MUOTRI, ALYSSON R. · 2022 to 2022
$706k
Illumina NovaSeq 6000 Sequencing SystemS10OD026929 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEPSEN, KRISTEN LYNN · 2019 to 2019
$600k
Alzheimer's disease and novel nanotherapeutics exclusively targeting extrasynaptic NMDA receptorsR43AG076088 · NIA · NEURANO BIOSCIENCE · PI MOLOKANOVA, ELENA · 2021 to 2022
$557k
California Institute for Regenerative Medicine (CIRM) DISC2-13866NIA NIH HHS R43 AG076088NIDA NIH HHS R44 DA050393NIEHS NIH HHS R01 ES033636NIH HHS S10 OD026929NIMH NIH HHS R01 MH123828NIMH NIH HHS R01 MH127077NIMH NIH HHS R43 MH124563NIMH NIH HHS R56 MH128365NINDS NIH HHS R01 NS105969NINDS NIH HHS R01 NS123160NINDS NIH HHS R01 NS123642NINDS NIH HHS R01 NS135055NINDS NIH HHS R43 NS122666NINDS NIH HHS U19 NS112959U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (NIEHS) 1R01ES033636U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) 1R01MH128365U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) 1R43MH124563U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH123828U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) 1R43NS122666U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R01NS123642U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) 1R43AG076088U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) 5R44DA050393
6 · The paper itself
Abstract
Light can serve as a tunable trigger for neurobioengineering technologies, enabling probing, control, and enhancement of brain function with unmatched spatiotemporal precision. Yet, these technologies often require genetic or structural alterations of neurons, disrupting their natural activity. Here, we introduce the Graphene-Mediated Optical Stimulation (GraMOS) platform, which leverages graphene's optoelectronic properties and its ability to efficiently convert light into electricity. Using GraMOS in longitudinal studies, we found that repeated optical stimulation enhances the maturation of hiPSC-derived neurons and brain organoids, underscoring GraMOS's potential for regenerative medicine and neurodevelopmental studies. To explore its potential for disease modeling, we applied short-term GraMOS to Alzheimer's stem cell models, uncovering disease-associated alterations in neuronal activity. Finally, we demonstrated a proof-of-concept for neuroengineering applications by directing robotic movements with GraMOS-triggered signals from graphene-interfaced brain organoids. By enabling precise, non-invasive neural control across timescales from milliseconds to months, GraMOS opens new avenues in neurodevelopment, disease treatment, and robotics.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Non-genetic neuromodulation with graphene optoelectronic actuators for disease models, stem cell maturation, and biohybrid robotics. · full record | OpenQuestion